Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

252 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Affimer-mediated locking of p21-activated kinase 5 in an intermediate activation state results in kinase inhibition.
Martin HL, Turner AL, Higgins J, Tang AA, Tiede C, Taylor T, Siripanthong S, Adams TL, Manfield IW, Bell SM, Morrison EE, Bond J, Trinh CH, Hurst CD, Knowles MA, Bayliss RW, Tomlinson DC. Martin HL, et al. Among authors: bayliss rw. Cell Rep. 2023 Oct 31;42(10):113184. doi: 10.1016/j.celrep.2023.113184. Epub 2023 Sep 29. Cell Rep. 2023. PMID: 37776520 Free article.
A Phase 2 Randomized Clinical Trial Evaluating 4-Dimensional Computed Tomography Ventilation-Based Functional Lung Avoidance Radiation Therapy for Non-Small Cell Lung Cancer.
Baschnagel AM, Flakus MJ, Wallat EM, Wuschner AE, Chappell RJ, Bayliss RA, Kimple RJ, Christensen GE, Reinhardt JM, Bassetti MF, Bayouth JE. Baschnagel AM, et al. Among authors: bayliss ra. Int J Radiat Oncol Biol Phys. 2024 Feb 20:S0360-3016(24)00327-4. doi: 10.1016/j.ijrobp.2024.02.019. Online ahead of print. Int J Radiat Oncol Biol Phys. 2024. PMID: 38387810
ALKing the flames of lung cancer immunosensitivity.
Bayliss R, Sarnowska E, Yeoh S, Sampson J. Bayliss R, et al. Mol Oncol. 2023 Nov;17(11):2218-2220. doi: 10.1002/1878-0261.13533. Epub 2023 Oct 12. Mol Oncol. 2023. PMID: 37795653 Free PMC article.
Using 18F-DCFPyL Prostate-Specific Membrane Antigen-Directed Positron Emission Tomography/Magnetic Resonance Imaging to Define Intraprostatic Boosts for Prostate Stereotactic Body Radiation Therapy.
Floberg JM, Wells SA, Ojala D, Bayliss RA, Hill PM, Morris BA, Morris ZS, Ritter M, Cho SY. Floberg JM, et al. Among authors: bayliss ra. Adv Radiat Oncol. 2023 Apr 9;8(5):101241. doi: 10.1016/j.adro.2023.101241. eCollection 2023 Sep-Oct. Adv Radiat Oncol. 2023. PMID: 37250282 Free PMC article.
Toxicity and Patient-Reported Quality-of-Life Outcomes After Prostate Stereotactic Body Radiation Therapy With Focal Boost to Magnetic Resonance Imaging-Identified Prostate Cancer Lesions: Results of a Phase 2 Trial.
Morris BA, Holmes EE, Anger NJ, Cooley G, Schuster JM, Hurst N, Baschnagel AM, Bassetti MF, Blitzer GC, Chappell RJ, Bayliss RA, Morris ZS, Ritter MA, Floberg JM. Morris BA, et al. Among authors: bayliss ra. Int J Radiat Oncol Biol Phys. 2023 Nov 1;117(3):613-623. doi: 10.1016/j.ijrobp.2023.05.004. Epub 2023 May 12. Int J Radiat Oncol Biol Phys. 2023. PMID: 37179035 Clinical Trial.
252 results